[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340252-105":3,"doc-detail-340252-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","utilizing-adenovirus-knob-proteins-as-carriers-in-cancer-gene-therapy-amidst-the-presence-of-anti-knob-antibodies","Utilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies","","Numerous cancer gene therapy drugs have obtained global approval, yet their efficacy against solid tumors remains insufficient. This study builds on the finding that adenovirus fiber protein can spread between cells that express the adenovirus receptor. The research identifies the adenovirus type 5 fiber knob region as a minimal, receptor-specific spreading unit and shows that a recombinant knob protein gains cell infiltration after neighboring-cell dispersal. In mice, a fusion of cytotoxic cholera toxin A subunit with the knob region suppresses tumor growth in receptor-expressing melanomas and retains activity under anti-knob antibodies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/utilizing-adenovirus-knob-proteins-as-carriers-in-cancer-gene-therapy-amidst-the-presence-of-anti-knob-antibodies/340252/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/utilizing-adenovirus-knob-proteins-as-carriers-in-cancer-gene-therapy-amidst-the-presence-of-anti-knob-antibodies/340252.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main hypothesis about adenovirus proteins in gene therapy?","Question",{"text":63,"@type":64},"The study hypothesizes that combining adenovirus fiber (or related units) with an anti-cancer protein could let the anti-cancer protein disseminate around transfected cells in a receptor-dependent manner.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which part of the adenovirus type 5 fiber is identified as capable of spreading to adjacent cells?",{"text":68,"@type":64},"The knob region of the adenovirus type 5 fiber protein is identified as the smallest unit capable of spreading to adjacent cells in a receptor-specific manner.",{"name":70,"@type":61,"acceptedAnswer":71},"Does the proposed fusion protein work even in the presence of anti-knob antibodies?",{"text":72,"@type":64},"Yes. The fusion protein inhibits tumor growth in receptor-expressing mouse melanomas, and the inhibitory effect persists even in mice with anti-knob antibodies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340252,1790104189,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0",8,"Article  \nUtilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies  \nNaoya Koizumi 1,*, Takamasa Hirai 1,2, Junpei Kano 1, Anna Sato 1, Yurika Suzuki 1, Arisa Sasaki 1, Tetsuya Nomura 1 and Naoki Utoguchi 1  \nCitation: Koizumi, N.; Hirai, T.; Kano, J.; Sato, A.; Suzuki, Y.; Sasaki, A.; Nomura, T.; Utoguchi, N. Utilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies. Int.  \nJ. Mol. Sci. 2024, 25, 10679. [https://](https://)[ ](https://)[doi.org/10.3390/ijms251910679](doi.org/10.3390/ijms251910679)  \nAcademic Editor: Pier Paolo Claudio  \nReceived: 5 August 2024  \nRevised: 28 September 2024  \nAccepted: 1 October 2024  \nPublished: 3 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Laboratory of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo 194-8543, Japan; [thirai@nihs.go.jp](thirai@nihs.go.jp) (T.H.); [nomura@ac.shoyaku.ac.jp](nomura@ac.shoyaku.ac.jp) (T.N.); [utoguchi@ac.shoyaku.ac.jp](utoguchi@ac.shoyaku.ac.jp) (N.U.)  \n2 Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kawasaki 210-9501, Japan  \n* Correspondence: [koizumi@ac.shoyaku.ac.jp](koizumi@ac.shoyaku.ac.jp); Tel.: +81-42-721-1556; Fax: +81-42-723-1556  \nAbstract: Numerous gene therapy drugs for cancer have received global approval, yet their efficacy against solid tumors remains inadequate. Our previous research indicated that the fiber protein, a component of the adenovirus capsid, can propagate from infected cells to neighboring cells that express the adenovirus receptor. We hypothesize that merging this fiber protein with an anti-cancer protein could enable the anti-cancer protein to disseminate around the transfected cells, presenting a novel approach to cancer gene therapy. In our study, we discovered that the knob region of the adenovirus type 5 fiber protein is the smallest unit capable of spreading to adjacent cells in a receptor-specific manner. We also showed that the recombinant knob protein infiltrates cells after dispersing to surrounding cells. To assess the potential of the knob protein to augment gene therapy for solid tumors in mice, we expressed a fusion gene of the A subunit of cytotoxic cholera toxin and the knob region in mouse tumors. We found that this fusion protein only inhibited tumor growth in receptor-expressing mouse melanomas, and this inhibitory effect persisted even in mice with anti-knob antibodies. Our study’s findings propose a novel cancer gene therapy strategy that enhances therapeutic effects by specifically delivering therapeutic proteins, expressed from in vivo administered genes, to target molecules. This outcome offers a fresh perspective on gene therapy for solid cancers, and we anticipate that knob proteins will serve as a platform for this method.  \nKeywords: targeting; gene therapy; knob protein; cancer; neutralizing antibodies  \n1. Introduction  \nCancer gene therapy has seen significant advancements in recent years. Notably, the complete response rates for acute B-cell lymphocytic leukemia and non-Hodgkin’s lymphoma using chimeric antigen receptor T (CAR-T) therapy have reached 90% and 60%, respectively. However, a meta-analysis of 22 studies revealed that the response rate ofchimeric antigen receptor (CAR)-T therapies in solid tumors was a mere 9%[1,2] .  \nVirotherapy utilizing oncolytic viruses (OVs) has demonstrated promising results in solid tumors. OVs are gaining attention due to their ability to selectively infect and eradicate tumor cells without harming normal cells, thanks to their cancer cell-specific proliferative","cbCaihfyi8HvxZFF","https://ap.wps.com/l/cbCaihfyi8HvxZFF","pdf",3208044,20,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Cancer gene therapy advances and solid tumor limitations\n## Oncolytic viruses and neutralizing antibodies\n## Conventional vectors and the need for improved delivery","[{\"question\":\"What is the study’s main hypothesis about adenovirus proteins in gene therapy?\",\"answer\":\"The study hypothesizes that combining adenovirus fiber (or related units) with an anti-cancer protein could let the anti-cancer protein disseminate around transfected cells in a receptor-dependent manner.\"},{\"question\":\"Which part of the adenovirus type 5 fiber is identified as capable of spreading to adjacent cells?\",\"answer\":\"The knob region of the adenovirus type 5 fiber protein is identified as the smallest unit capable of spreading to adjacent cells in a receptor-specific manner.\"},{\"question\":\"Does the proposed fusion protein work even in the presence of anti-knob antibodies?\",\"answer\":\"Yes. The fusion protein inhibits tumor growth in receptor-expressing mouse melanomas, and the inhibitory effect persists even in mice with anti-knob antibodies.\"}]","Utilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies | PDF",1790035254,50,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/875c9032aaa47038da9a9ccb51cfac20.webp",983,1390,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1b035b0e303f46fe046caafb88c5c36.webp",982,1388,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae59664306f91163ec76bb92188cd05b.webp",981,1387,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b578a20edf17ebfaaf5c0f69d71b90a.webp",980,1385,{"code":4,"msg":82,"data":117},[118,122,126,130,135,139,144,147,150,153,157],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":98,"slug":138},6,"Technology","technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":148,"show_sort_weight":92,"slug":149},"Religion & Spirituality","religion-spirituality",{"id":92,"doc_module":4,"doc_module_name":25,"category_name":151,"show_sort_weight":92,"slug":152},"World Cup","world-cup",{"id":154,"doc_module":4,"doc_module_name":25,"category_name":155,"show_sort_weight":154,"slug":156},10,"Lifestyle","lifestyle",{"id":158,"doc_module":4,"doc_module_name":25,"category_name":159,"show_sort_weight":131,"slug":160},19,"General","general"]